Bio Pharma Dive
OCTOBER 25, 2021
The barrier to knowledge can be eliminated when pharmaceutical companies use natural language processing to analyze unstructured content.
World of DTC Marketing
OCTOBER 25, 2021
SUMMARY: One definitive trend to emerge from the pandemic is that more people are becoming healthcare consumers. They want healthcare to be easier to access and don’t want to wait for necessary medical tests. This could lead to an evolution in urgent care centers, but it will require disruptive thinking. Urgent care centers aren’t new, but they are evolving to become “total care” in some areas.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
OCTOBER 26, 2021
The drug acts by inhibiting SARS-CoV-2 from replicating in the human system
Pharma Mirror
OCTOBER 29, 2021
Petrovax Pharm, the Russian biopharmaceutical company, will participate in CPhI Worldwide-2021 – the international specialized pharmaceutical industry exhibition. This year, it will be held from 9 to 11 November in Italy (Milan) on Fiera Milano territory’s largest exhibition complex. At the exhibition stand, Petrovax Pharm will present its original pharmaceutical products, that are the flagships of the product portfolio – the immunomodulator Polyoxidonium®, the enzyme preparation Lon
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
OCTOBER 26, 2021
A new alliance with Mammoth Biosciences marks the latest evidence of Vertex's interest in gene editing, which has already been the focus of multiple deals with emerging biotechs.
World of DTC Marketing
OCTOBER 27, 2021
SUMMARY : DTC message development and use is the most essential action to get patients interested in your product, but it can’t be based on unrealistic patient behavior modifications. Yesterday I received a call from a physician who is a thought leader in the diabetes area. He had read my BLOG post from yesterday and wanted to add something that he thinks DTC marketers need to hear. “Don’t promise results that most patients will never see.” As we talked, he mentioned a di
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Mirror
OCTOBER 29, 2021
You may not realize it, but your community pharmacist does so much more than fill the prescriptions your primary healthcare provider writes for you. In fact, pharmacists are vital to the health and wellness of the people in the areas they serve on the front line, and they play a key role when it comes to medication adherence. Pharmacists help their communities and, indeed, the medical industry as a whole by administering vaccinations, making drug recommendations, providing access to medical care
Bio Pharma Dive
OCTOBER 27, 2021
The Japanese drugmaker is acquiring GammaDelta Therapeutics, a partner since 2017, and its research on allogeneic cell therapy for cancer.
World of DTC Marketing
OCTOBER 26, 2021
LEAD-IN: “What is the reason to believe?” It seems like a simple question, doesn’t it yet? In today’s micro-segmented audience environment, it’s often hard to come up with one reason that might resonate with everyone in your target audience. I’ve noticed a trend that’s been emerging in the last couple of years.
Pharma Times
OCTOBER 29, 2021
Experts say that it is vital to ensure that every member who is eligible for a vaccine has received one
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharma Mirror
OCTOBER 29, 2021
Terrassa (Barcelona). Telstar will be actively participating at CPhI, to be held in Milan, during 9-11th November 2021, promoting its personalized GMP consultancy & engineering reply to the new trends in pharma. The company will be displaying high-tech solutions in design, engineering and construction including complete and integrated turnkey pharmaceutical process production facilities, critical installations, clean rooms, biotechnological plants, critical process facilities and R&D lab
Bio Pharma Dive
OCTOBER 27, 2021
The deal with the Medicines Patent Pool is meant to increase access in lower-income countries to molnupiravir, an experimental drug that could become the first oral treatment for COVID-19.
BioSpace
OCTOBER 26, 2021
The decision to move forward with the trial comes on the heels of the FDA's approval of its IND application, allowing Cleveland Clinic and Anixa Biosciences to proceed.
Pharma Times
OCTOBER 25, 2021
Package was announced during a speech at the annual Conservative Party Conference in Manchester, UK
Pharma Mirror
OCTOBER 28, 2021
Amsterdam, The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030. The analysis foresees the use of automated cobots, AI, real-time release and rapid growth in new areas like mRNA vaccines, alongside the personalization of therapeutics (delivered at far larger scale).
Bio Pharma Dive
OCTOBER 29, 2021
The authorization makes the shot available to nearly 28 million kids between the ages of 5 and 11, though a CDC panel next week could hold significant sway over who among them should be vaccinated.
pharmaphorum
OCTOBER 25, 2021
Expectations for Novartis’ canakinumab as a therapy for cancer have taken another dive, after a second phase 3 trial in non-small cell lung cancer (NSCLC) failed to meet its primary objectives. Novartis isn’t giving up on the programme yet, as it still has other trials of canakinumab in play, but the latest failure makes prospects for the antibody in oncology look increasingly remote.
Pharma Times
OCTOBER 25, 2021
Approval covers patients with locally recurrent or metastatic TNBC
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Mirror
OCTOBER 26, 2021
Castle Creek Biosciences Inc., a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options, has formed a new research collaboration with Mayo Clinic. The partnership was forged under the leadership of Castle Creek President and CEO, Mathew Gantz, and direction from Founder and Chairman Jeff Aronin.
Bio Pharma Dive
OCTOBER 26, 2021
The expert panel pressed Pfizer and the FDA on the shot's safety, but ultimately were convinced by the potential for significant benefit in 5- to 11-year-olds.
pharmaphorum
OCTOBER 27, 2021
Bayer’s two-year-old digital health collaboration with One Drop has borne its first fruit, an artificial intelligence-powered software module for preventing cardiovascular disease (CVD). The German pharmaceutical company has been working with New York-based One Drop on digital health products that span multiple therapeutic areas, including oncology and women’s health as well as CVD in the alliance , which was expanded last year in a $98 million deal.
Pharma Times
OCTOBER 26, 2021
Tucatinib, a tyrosine kinase inhibitor, works by blocking a specific area of the HER2 gene in cancer cells
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Outsourcing Pharma
OCTOBER 26, 2021
Appili Therapeutics reports it has enrolled the last patient for its Phase III study of Avigan/Reeqonus (favipiravir), developed in alliance with AiPharma.
Bio Pharma Dive
OCTOBER 28, 2021
Executives based their projections on contracts already in place for the drug, known as molnupiravir. But sales could climb even higher if it works as a preventive treatment too.
pharmaphorum
OCTOBER 26, 2021
COVID-19 demonstrated the importance of robust supply chains and the dangers of an over reliance on overseas manufacturing. But can the Pharmaceutical Strategy for Europe help to redress the balance? Only sustainable, robust supply chains and business models will allow innovation to flourish, secure access to medicines, and minimise the industry’s impact on the environment.
Pharma Times
OCTOBER 25, 2021
Product designed to allow laboratories to expand in-house oncology research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
BioSpace
OCTOBER 26, 2021
Nuravax is developing a vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins associated with both AD and Parkinson's disease.
Bio Pharma Dive
OCTOBER 26, 2021
Outside experts are reviewing Pfizer's application for emergency authorization of its vaccine in 5- to 11-year-olds. Follow their discussion with BioPharma Dive reporters live.
pharmaphorum
OCTOBER 26, 2021
Novartis revealed today that it may consider divesting its generic medicines subsidiary Sandoz – amongst other options – which would further narrow its focus to innovative medicines. The company said in its third-quarter results statement that it was weighing options for Sandoz to “maximise shareholder value,” adding that could include retaining the business or a separation – which could involve a spin-off or outright sale.
Pharma Times
OCTOBER 27, 2021
Partnership will see DNAe, Imperial College London and the University of Leicester collaborate on early detection of recurrent breast cancer
Expert insights. Personalized for you.
361 
Let's personalize your content